Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as…
| Price | $237.28 |
|---|---|
| Market cap | $14.05B |
| Sector | Healthcare |
| Industry | Medical - Devices |
| Exchange | NYSE |
| 52-week range | 80.905-248.75 |
| Beta | 0.69 |
Explore GKOS's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.